Trial Outcomes & Findings for Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid Leukemia (NCT NCT01876953)
NCT ID: NCT01876953
Last Updated: 2022-03-31
Results Overview
Maximum tolerated dose of dasatinib, determined according to incidence of dose limiting toxicity (DLT), graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (Phase I)
Recruitment status
TERMINATED
Study phase
PHASE1/PHASE2
Target enrollment
20 participants
Primary outcome timeframe
From the first dose of Dasatinib through the DLT observation period (Day +28)
Results posted on
2022-03-31
Participant Flow
Due to the funding issue, the study was stopped early before reaching the target accrual. However, all the enrolled patients had received the treatment drug per protocol.
Participant milestones
| Measure |
Dasatinib 100mg/Day + Cytarabine 200mg/m2/Day + Idarubicin 12mg/m2/Day
Patients receive cytarabine IV continuously over 168 hours on days 1-7, dasatinib PO QD on days 1-7, and idarubicin hydrochloride IV on days 1-3. Patients with non-responsive disease on day 30 may receive a second course of therapy (re-induction therapy) within 1 week in the absence of unacceptable toxicity.
cytarabine: Given IV
idarubicin: Given IV
dasatinib: Given PO
laboratory biomarker analysis: Correlative studies
|
Dasatinib 140mg/Day + Cytarabine 200mg/m2/Day + Idarubicin 12mg/m2/Day
Patients receive cytarabine IV continuously over 168 hours on days 1-7, dasatinib PO QD on days 1-7, and idarubicin hydrochloride IV on days 1-3. Patients with non-responsive disease on day 30 may receive a second course of therapy (re-induction therapy) within 1 week in the absence of unacceptable toxicity.
cytarabine: Given IV
idarubicin: Given IV
dasatinib: Given PO
laboratory biomarker analysis: Correlative studies
|
|---|---|---|
|
Overall Study
STARTED
|
17
|
3
|
|
Overall Study
COMPLETED
|
17
|
3
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid Leukemia
Baseline characteristics by cohort
| Measure |
Dasatinib 100mg/Day + Cytarabine 200mg/m2/Day + Idarubicin 12mg/m2/Day
n=17 Participants
Patients receive cytarabine IV continuously over 168 hours on days 1-7, dasatinib PO QD on days 1-7, and idarubicin hydrochloride IV on days 1-3. Patients with non-responsive disease on day 30 may receive a second course of therapy (re-induction therapy) within 1 week in the absence of unacceptable toxicity.
cytarabine: Given IV
idarubicin: Given IV
dasatinib: Given PO
laboratory biomarker analysis: Correlative studies
|
Dasatinib 140mg/Day + Cytarabine 200mg/m2/Day + Idarubicin 12mg/m2/Day
n=3 Participants
Patients receive cytarabine IV continuously over 168 hours on days 1-7, dasatinib PO QD on days 1-7, and idarubicin hydrochloride IV on days 1-3. Patients with non-responsive disease on day 30 may receive a second course of therapy (re-induction therapy) within 1 week in the absence of unacceptable toxicity.
cytarabine: Given IV
idarubicin: Given IV
dasatinib: Given PO
laboratory biomarker analysis: Correlative studies
|
Total
n=20 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
|
62 years
n=5 Participants
|
63 years
n=7 Participants
|
63 years
n=5 Participants
|
|
Sex: Female, Male
Female
|
4 Participants
n=5 Participants
|
1 Participants
n=7 Participants
|
5 Participants
n=5 Participants
|
|
Sex: Female, Male
Male
|
13 Participants
n=5 Participants
|
2 Participants
n=7 Participants
|
15 Participants
n=5 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
2 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
2 Participants
n=5 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
15 Participants
n=5 Participants
|
3 Participants
n=7 Participants
|
18 Participants
n=5 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Asian
|
3 Participants
n=5 Participants
|
1 Participants
n=7 Participants
|
4 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Black or African American
|
1 Participants
n=5 Participants
|
1 Participants
n=7 Participants
|
2 Participants
n=5 Participants
|
|
Race (NIH/OMB)
White
|
12 Participants
n=5 Participants
|
1 Participants
n=7 Participants
|
13 Participants
n=5 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
1 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
1 Participants
n=5 Participants
|
|
Region of Enrollment
United States
|
17 Participants
n=5 Participants
|
3 Participants
n=7 Participants
|
20 Participants
n=5 Participants
|
PRIMARY outcome
Timeframe: From the first dose of Dasatinib through the DLT observation period (Day +28)Population: Six patients treated at 100 mg/m2 in Phase I are evaluable for dose limiting toxicity.
Maximum tolerated dose of dasatinib, determined according to incidence of dose limiting toxicity (DLT), graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (Phase I)
Outcome measures
| Measure |
Dasatinib 100mg/Day + Cytarabine 200mg/m2/Day + Idarubicin 12mg/m2/Day
n=6 Participants
Patients receive cytarabine IV continuously over 168 hours on days 1-7, dasatinib PO QD on days 1-7, and idarubicin hydrochloride IV on days 1-3. Patients with non-responsive disease on day 30 may receive a second course of therapy (re-induction therapy) within 1 week in the absence of unacceptable toxicity.
cytarabine: Given IV
idarubicin: Given IV
dasatinib: Given PO
laboratory biomarker analysis: Correlative studies
|
Dasatinib 140mg/Day + Cytarabine 200mg/m2/Day + Idarubicin 12mg/m2/Day
Patients receive cytarabine IV continuously over 168 hours on days 1-7, dasatinib PO QD on days 1-7, and idarubicin hydrochloride IV on days 1-3. Patients with non-responsive disease on day 30 may receive a second course of therapy (re-induction therapy) within 1 week in the absence of unacceptable toxicity.
cytarabine: Given IV
idarubicin: Given IV
dasatinib: Given PO
laboratory biomarker analysis: Correlative studies
|
|---|---|---|
|
Maximum Tolerated Dose of Dasatinib (Phase I)
|
100 mg/m2
|
—
|
PRIMARY outcome
Timeframe: From the first cycle up to two yearsPopulation: The study was terminated before the data were mature enough to estimate the CR rate. Therefore, the overall number of participants who were evaluable is zero.
Remission rates will be calculated as the percent of evaluable patients that have a confirmed CR, and exact 95% confidence intervals will be calculated for these estimates.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Time from start of study therapy until death, or last contact, whichever comes first, assessed up to 2 yearsPopulation: The study was terminated before the data were mature enough to estimate the overall survival outcomes. Therefore, the overall number of participants who were evaluable is zero.
Overall survival was measured from the first dose of Dasatinib to death from any cause or last contact, whichever comes first. It was estimated using the product-limit method of Kaplan and Meier.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Time from start of study therapy until death, relapse/progression, receipt of anti-leukemia therapy, or last contact, whichever comes first, assessed up to two years.Population: The study was terminated before the data were mature enough to estimate the even-free survival. Therefore, the overall number of participants who were evaluable is zero.
Event-free survival was defined as time from the first dose of Dasatinib to relapse/progression, receipt of anti-leukemia therapy, death, or last contact, whichever comes first. It was estimated using the product-limit method of Kaplan and Meier.
Outcome measures
Outcome data not reported
Adverse Events
Dasatinib 100mg/Day + Cytarabine 200mg/m2/Day + Idarubicin 12mg/m2/Day
Serious events: 4 serious events
Other events: 17 other events
Deaths: 11 deaths
Dasatinib 140mg/Day + Cytarabine 200mg/m2/Day + Idarubicin 12mg/m2/Day
Serious events: 0 serious events
Other events: 3 other events
Deaths: 3 deaths
Serious adverse events
| Measure |
Dasatinib 100mg/Day + Cytarabine 200mg/m2/Day + Idarubicin 12mg/m2/Day
n=17 participants at risk
Patients receive cytarabine IV continuously over 168 hours on days 1-7, dasatinib PO QD on days 1-7, and idarubicin hydrochloride IV on days 1-3. Patients with non-responsive disease on day 30 may receive a second course of therapy (re-induction therapy) within 1 week in the absence of unacceptable toxicity.
cytarabine: Given IV
idarubicin: Given IV
dasatinib: Given PO
laboratory biomarker analysis: Correlative studies
|
Dasatinib 140mg/Day + Cytarabine 200mg/m2/Day + Idarubicin 12mg/m2/Day
n=3 participants at risk
Patients receive cytarabine IV continuously over 168 hours on days 1-7, dasatinib PO QD on days 1-7, and idarubicin hydrochloride IV on days 1-3. Patients with non-responsive disease on day 30 may receive a second course of therapy (re-induction therapy) within 1 week in the absence of unacceptable toxicity.
cytarabine: Given IV
idarubicin: Given IV
dasatinib: Given PO
laboratory biomarker analysis: Correlative studies
|
|---|---|---|
|
General disorders
Death NOS
|
5.9%
1/17 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
General disorders
Multi-organ failure
|
5.9%
1/17 • Number of events 2 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Nervous system disorders
Intracranial hemorrhage
|
5.9%
1/17 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Respiratory, thoracic and mediastinal disorders
Adult respiratory distress syndrome
|
5.9%
1/17 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Respiratory, thoracic and mediastinal disorders
Hypoxia
|
5.9%
1/17 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Respiratory, thoracic and mediastinal disorders
Respiratory failure
|
5.9%
1/17 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
Other adverse events
| Measure |
Dasatinib 100mg/Day + Cytarabine 200mg/m2/Day + Idarubicin 12mg/m2/Day
n=17 participants at risk
Patients receive cytarabine IV continuously over 168 hours on days 1-7, dasatinib PO QD on days 1-7, and idarubicin hydrochloride IV on days 1-3. Patients with non-responsive disease on day 30 may receive a second course of therapy (re-induction therapy) within 1 week in the absence of unacceptable toxicity.
cytarabine: Given IV
idarubicin: Given IV
dasatinib: Given PO
laboratory biomarker analysis: Correlative studies
|
Dasatinib 140mg/Day + Cytarabine 200mg/m2/Day + Idarubicin 12mg/m2/Day
n=3 participants at risk
Patients receive cytarabine IV continuously over 168 hours on days 1-7, dasatinib PO QD on days 1-7, and idarubicin hydrochloride IV on days 1-3. Patients with non-responsive disease on day 30 may receive a second course of therapy (re-induction therapy) within 1 week in the absence of unacceptable toxicity.
cytarabine: Given IV
idarubicin: Given IV
dasatinib: Given PO
laboratory biomarker analysis: Correlative studies
|
|---|---|---|
|
Blood and lymphatic system disorders
10002272-Anemia
|
94.1%
16/17 • Number of events 83 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
100.0%
3/3 • Number of events 3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Blood and lymphatic system disorders
10016288-Febrile neutropenia
|
29.4%
5/17 • Number of events 12 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Blood and lymphatic system disorders
Markedly irregular multilobulated spleen with linear calcification
|
0.00%
0/17 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
33.3%
1/3 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Blood and lymphatic system disorders
Splenomegaly
|
5.9%
1/17 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Cardiac disorders
10003658-Atrial fibrillation
|
5.9%
1/17 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Cardiac disorders
10003662-Atrial flutter
|
5.9%
1/17 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Cardiac disorders
10034474-Pericardial effusion
|
5.9%
1/17 • Number of events 2 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
66.7%
2/3 • Number of events 2 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Cardiac disorders
10040741-Sinus bradycardia
|
35.3%
6/17 • Number of events 12 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Cardiac disorders
10040752-Sinus tachycardia
|
70.6%
12/17 • Number of events 34 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
33.3%
1/3 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Cardiac disorders
Atherosclerotic Vascular Disease
|
0.00%
0/17 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
33.3%
1/3 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Cardiac disorders
Left atrial enlargment
|
0.00%
0/17 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
33.3%
1/3 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Cardiac disorders
Nonspecific ST and T wave abnormality
|
5.9%
1/17 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Cardiac disorders
cardiomegaly
|
5.9%
1/17 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Cardiac disorders
cardiomyopathy
|
5.9%
1/17 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Ear and labyrinth disorders
10065837-External ear inflammation
|
5.9%
1/17 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Ear and labyrinth disorders
Mastoiditis
|
5.9%
1/17 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Ear and labyrinth disorders
right ear hearing loss
|
5.9%
1/17 • Number of events 3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Endocrine disorders
syndrome of inappropriate antidiuretic hormone
|
5.9%
1/17 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Eye disorders
10005886-Blurred vision
|
5.9%
1/17 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Eye disorders
10013774-Dry eye
|
11.8%
2/17 • Number of events 4 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
33.3%
1/3 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Eye disorders
10047848-Watering eyes
|
5.9%
1/17 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Eye disorders
redness, jaundice, sclera/conjunctiva discoloration
|
0.00%
0/17 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
33.3%
1/3 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Eye disorders
scleral hemmorage
|
5.9%
1/17 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Eye disorders
scleral hemorage
|
5.9%
1/17 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Gastrointestinal disorders
10000060-Abdominal distension
|
17.6%
3/17 • Number of events 4 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Gastrointestinal disorders
10000081-Abdominal pain
|
35.3%
6/17 • Number of events 6 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
66.7%
2/3 • Number of events 2 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Gastrointestinal disorders
10003445-Ascites
|
5.9%
1/17 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
33.3%
1/3 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Gastrointestinal disorders
10009887-Colitis
|
5.9%
1/17 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Gastrointestinal disorders
10010774-Constipation
|
41.2%
7/17 • Number of events 10 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
33.3%
1/3 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Gastrointestinal disorders
10012727-Diarrhea
|
70.6%
12/17 • Number of events 24 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
100.0%
3/3 • Number of events 3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Gastrointestinal disorders
10013781-Dry mouth
|
29.4%
5/17 • Number of events 8 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Gastrointestinal disorders
10013946-Dyspepsia
|
17.6%
3/17 • Number of events 5 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
33.3%
1/3 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Gastrointestinal disorders
10013950-Dysphagia
|
23.5%
4/17 • Number of events 5 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Gastrointestinal disorders
10015388-Esophageal pain
|
5.9%
1/17 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Gastrointestinal disorders
10016296-Fecal incontinence
|
5.9%
1/17 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Gastrointestinal disorders
10017999-Gastrointestinal pain
|
11.8%
2/17 • Number of events 2 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Gastrointestinal disorders
10018286-Gingival pain
|
5.9%
1/17 • Number of events 2 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Gastrointestinal disorders
10019611-Hemorrhoids
|
5.9%
1/17 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
66.7%
2/3 • Number of events 2 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Gastrointestinal disorders
10028130-Mucositis oral
|
52.9%
9/17 • Number of events 21 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
66.7%
2/3 • Number of events 2 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Gastrointestinal disorders
10028813-Nausea
|
76.5%
13/17 • Number of events 27 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
100.0%
3/3 • Number of events 3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Gastrointestinal disorders
10031009-Oral pain
|
17.6%
3/17 • Number of events 4 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Gastrointestinal disorders
10038072-Rectal pain
|
11.8%
2/17 • Number of events 2 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Gastrointestinal disorders
10044055-Toothache
|
5.9%
1/17 • Number of events 2 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Gastrointestinal disorders
10047700-Vomiting
|
52.9%
9/17 • Number of events 12 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Gastrointestinal disorders
10055356-Upper gastrointestinal hemorrhage
|
5.9%
1/17 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Gastrointestinal disorders
Anal fissure
|
0.00%
0/17 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
33.3%
1/3 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Gastrointestinal disorders
Inguinal hernias
|
0.00%
0/17 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
33.3%
1/3 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
General disorders
10008531-Chills
|
23.5%
4/17 • Number of events 5 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
General disorders
10014222-Edema face
|
11.8%
2/17 • Number of events 3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
General disorders
10016059-Facial pain
|
5.9%
1/17 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
General disorders
10016256-Fatigue
|
58.8%
10/17 • Number of events 26 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
100.0%
3/3 • Number of events 3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
General disorders
10016558-Fever
|
76.5%
13/17 • Number of events 36 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
66.7%
2/3 • Number of events 3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
General disorders
10017577-Gait disturbance
|
5.9%
1/17 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
General disorders
10022095-Injection site reaction
|
5.9%
1/17 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
General disorders
10025482-Malaise
|
5.9%
1/17 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
33.3%
1/3 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
General disorders
10033371-Pain
|
23.5%
4/17 • Number of events 5 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
General disorders
10050068-Edema limbs
|
52.9%
9/17 • Number of events 17 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
100.0%
3/3 • Number of events 3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
General disorders
10051792-Infusion related reaction
|
5.9%
1/17 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
General disorders
10062466-Localized edema
|
5.9%
1/17 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
General disorders
10062501-Non-cardiac chest pain
|
17.6%
3/17 • Number of events 3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
33.3%
1/3 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
General disorders
generalized edema
|
5.9%
1/17 • Number of events 2 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Hepatobiliary disorders
biliary dyskinesia
|
5.9%
1/17 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Infections and infestations
10007810-Catheter related infection
|
11.8%
2/17 • Number of events 2 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Infections and infestations
10019799-Hepatitis viral
|
5.9%
1/17 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Infections and infestations
10040047-Sepsis
|
11.8%
2/17 • Number of events 2 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Infections and infestations
10040753-Sinusitis
|
0.00%
0/17 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
33.3%
1/3 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Infections and infestations
10048038-Wound infection
|
5.9%
1/17 • Number of events 2 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Infections and infestations
10048762-Tooth infection
|
5.9%
1/17 • Number of events 2 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Infections and infestations
10061229-Lung infection
|
11.8%
2/17 • Number of events 3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
33.3%
1/3 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Infections and infestations
10062255-Soft tissue infection
|
5.9%
1/17 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Infections and infestations
10069138-Papulopustular rash
|
5.9%
1/17 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Infections and infestations
Candida Glabrata
|
0.00%
0/17 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
33.3%
1/3 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Infections and infestations
Enterococci Faecium
|
0.00%
0/17 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
33.3%
1/3 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Infections and infestations
Mastoiditis Grade 1 CT scan dated 10/9
|
5.9%
1/17 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Infections and infestations
Staphylococcus Coagulase Negative
|
0.00%
0/17 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
33.3%
1/3 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Infections and infestations
Streptococcus viridans bacteremi
|
5.9%
1/17 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Infections and infestations
Upper lip herpetic lesion
|
0.00%
0/17 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
33.3%
1/3 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Injury, poisoning and procedural complications
10006504-Bruising
|
11.8%
2/17 • Number of events 2 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Injury, poisoning and procedural complications
10016173-Fall
|
5.9%
1/17 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Investigations
10000636-Activated partial thromboplastin time prolonged
|
0.00%
0/17 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
33.3%
1/3 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Investigations
10001551-Alanine aminotransferase increased
|
52.9%
9/17 • Number of events 12 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
66.7%
2/3 • Number of events 2 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Investigations
10001675-Alkaline phosphatase increased
|
35.3%
6/17 • Number of events 7 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
66.7%
2/3 • Number of events 2 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Investigations
10003481-Aspartate aminotransferase increased
|
52.9%
9/17 • Number of events 16 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
33.3%
1/3 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Investigations
10005364-Blood bilirubin increased
|
64.7%
11/17 • Number of events 34 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
100.0%
3/3 • Number of events 3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Investigations
10007612-Cardiac troponin I increased
|
5.9%
1/17 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Investigations
10011368-Creatinine increased
|
29.4%
5/17 • Number of events 5 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Investigations
10022402-INR increased
|
0.00%
0/17 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
33.3%
1/3 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Investigations
10025256-Lymphocyte count decreased
|
88.2%
15/17 • Number of events 44 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
100.0%
3/3 • Number of events 3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Investigations
10025258-Lymphocyte count increased
|
0.00%
0/17 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
33.3%
1/3 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Investigations
10029366-Neutrophil count decreased
|
70.6%
12/17 • Number of events 24 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
100.0%
3/3 • Number of events 3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Investigations
10035528-Platelet count decreased
|
100.0%
17/17 • Number of events 119 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
100.0%
3/3 • Number of events 3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Investigations
10047896-Weight gain
|
35.3%
6/17 • Number of events 13 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
66.7%
2/3 • Number of events 2 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Investigations
10047900-Weight loss
|
52.9%
9/17 • Number of events 17 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
33.3%
1/3 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Investigations
10049182-White blood cell decreased
|
94.1%
16/17 • Number of events 37 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
33.3%
1/3 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Investigations
10050528-Ejection fraction decreased
|
5.9%
1/17 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Investigations
10056910-GGT increased
|
5.9%
1/17 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Metabolism and nutrition disorders
10000486-Acidosis
|
11.8%
2/17 • Number of events 4 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Metabolism and nutrition disorders
10001680-Alkalosis
|
11.8%
2/17 • Number of events 5 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Metabolism and nutrition disorders
10002646-Anorexia
|
58.8%
10/17 • Number of events 19 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
66.7%
2/3 • Number of events 2 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Metabolism and nutrition disorders
10020639-Hyperglycemia
|
17.6%
3/17 • Number of events 4 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Metabolism and nutrition disorders
10020670-Hypermagnesemia
|
29.4%
5/17 • Number of events 5 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
33.3%
1/3 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Metabolism and nutrition disorders
10020680-Hypernatremia
|
5.9%
1/17 • Number of events 3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Metabolism and nutrition disorders
10020870-Hypertriglyceridemia
|
11.8%
2/17 • Number of events 2 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Metabolism and nutrition disorders
10020907-Hyperuricemia
|
11.8%
2/17 • Number of events 2 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Metabolism and nutrition disorders
10020943-Hypoalbuminemia
|
76.5%
13/17 • Number of events 49 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
100.0%
3/3 • Number of events 3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Metabolism and nutrition disorders
10020949-Hypocalcemia
|
70.6%
12/17 • Number of events 25 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
66.7%
2/3 • Number of events 2 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Metabolism and nutrition disorders
10021005-Hypoglycemia
|
5.9%
1/17 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Metabolism and nutrition disorders
10021018-Hypokalemia
|
70.6%
12/17 • Number of events 42 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
100.0%
3/3 • Number of events 3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Metabolism and nutrition disorders
10021028-Hypomagnesemia
|
23.5%
4/17 • Number of events 5 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
33.3%
1/3 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Metabolism and nutrition disorders
10021038-Hyponatremia
|
94.1%
16/17 • Number of events 37 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
66.7%
2/3 • Number of events 2 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Metabolism and nutrition disorders
10021059-Hypophosphatemia
|
35.3%
6/17 • Number of events 9 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Metabolism and nutrition disorders
10029883-Obesity
|
5.9%
1/17 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Musculoskeletal and connective tissue disorders
10003239-Arthralgia
|
5.9%
1/17 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Musculoskeletal and connective tissue disorders
10003246-Arthritis
|
5.9%
1/17 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Musculoskeletal and connective tissue disorders
10003988-Back pain
|
41.2%
7/17 • Number of events 13 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
100.0%
3/3 • Number of events 4 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Musculoskeletal and connective tissue disorders
10006002-Bone pain
|
5.9%
1/17 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Musculoskeletal and connective tissue disorders
10016750-Flank pain
|
11.8%
2/17 • Number of events 2 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Musculoskeletal and connective tissue disorders
10028411-Myalgia
|
0.00%
0/17 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
33.3%
1/3 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Musculoskeletal and connective tissue disorders
10028836-Neck pain
|
17.6%
3/17 • Number of events 5 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Musculoskeletal and connective tissue disorders
10033425-Pain in extremity
|
17.6%
3/17 • Number of events 4 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
100.0%
3/3 • Number of events 5 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Musculoskeletal and connective tissue disorders
10048706-Joint range of motion decreased
|
5.9%
1/17 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Musculoskeletal and connective tissue disorders
10062572-Generalized muscle weakness
|
17.6%
3/17 • Number of events 5 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Musculoskeletal and connective tissue disorders
neck stiffness
|
5.9%
1/17 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Nervous system disorders
10012373-Depressed level of consciousness
|
5.9%
1/17 • Number of events 3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Nervous system disorders
10013911-Dysgeusia
|
5.9%
1/17 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Nervous system disorders
10019211-Headache
|
52.9%
9/17 • Number of events 22 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
33.3%
1/3 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Nervous system disorders
10024264-Lethargy
|
11.8%
2/17 • Number of events 2 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Nervous system disorders
10027175-Memory impairment
|
17.6%
3/17 • Number of events 3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Nervous system disorders
10034620-Peripheral sensory neuropathy
|
5.9%
1/17 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Nervous system disorders
10039906-Seizure
|
11.8%
2/17 • Number of events 2 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Nervous system disorders
10041349-Somnolence
|
17.6%
3/17 • Number of events 4 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Nervous system disorders
10044565-Tremor
|
5.9%
1/17 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Nervous system disorders
seizure-like disorder, altered mental status
|
5.9%
1/17 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Psychiatric disorders
10001497-Agitation
|
23.5%
4/17 • Number of events 6 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
33.3%
1/3 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Psychiatric disorders
10002855-Anxiety
|
41.2%
7/17 • Number of events 12 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Psychiatric disorders
10010300-Confusion
|
17.6%
3/17 • Number of events 3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
33.3%
1/3 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Psychiatric disorders
10012378-Depression
|
11.8%
2/17 • Number of events 2 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
33.3%
1/3 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Psychiatric disorders
10022437-Insomnia
|
29.4%
5/17 • Number of events 14 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
100.0%
3/3 • Number of events 3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Psychiatric disorders
10038743-Restlessness
|
23.5%
4/17 • Number of events 7 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Renal and urinary disorders
10019450-Hematuria
|
11.8%
2/17 • Number of events 2 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Renal and urinary disorders
10037032-Proteinuria
|
17.6%
3/17 • Number of events 3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
33.3%
1/3 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Renal and urinary disorders
10046539-Urinary frequency
|
5.9%
1/17 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Renal and urinary disorders
10046543-Urinary incontinence
|
17.6%
3/17 • Number of events 3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Renal and urinary disorders
10069339-Acute kidney injury
|
11.8%
2/17 • Number of events 2 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Reproductive system and breast disorders
10013934-Dysmenorrhea
|
5.9%
1/17 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Reproductive system and breast disorders
10018146-Genital edema
|
11.8%
2/17 • Number of events 7 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Reproductive system and breast disorders
10039757-Scrotal pain
|
5.9%
1/17 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Reproductive system and breast disorders
10046912-Vaginal hemorrhage
|
11.8%
2/17 • Number of events 3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Reproductive system and breast disorders
Thickened Endometrium
|
5.9%
1/17 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Respiratory, thoracic and mediastinal disorders
10003598-Atelectasis
|
11.8%
2/17 • Number of events 2 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
33.3%
1/3 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Respiratory, thoracic and mediastinal disorders
10011224-Cough
|
23.5%
4/17 • Number of events 5 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
100.0%
3/3 • Number of events 3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Respiratory, thoracic and mediastinal disorders
10013963-Dyspnea
|
29.4%
5/17 • Number of events 12 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
33.3%
1/3 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Respiratory, thoracic and mediastinal disorders
10020201-Hoarseness
|
11.8%
2/17 • Number of events 2 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Respiratory, thoracic and mediastinal disorders
10021143-Hypoxia
|
23.5%
4/17 • Number of events 5 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Respiratory, thoracic and mediastinal disorders
10028735-Nasal congestion
|
5.9%
1/17 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
33.3%
1/3 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Respiratory, thoracic and mediastinal disorders
10035598-Pleural effusion
|
23.5%
4/17 • Number of events 4 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
100.0%
3/3 • Number of events 3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Respiratory, thoracic and mediastinal disorders
10035623-Pleuritic pain
|
11.8%
2/17 • Number of events 2 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Respiratory, thoracic and mediastinal disorders
10035742-Pneumonitis
|
17.6%
3/17 • Number of events 3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Respiratory, thoracic and mediastinal disorders
10036402-Postnasal drip
|
5.9%
1/17 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Respiratory, thoracic and mediastinal disorders
10036790-Productive cough
|
5.9%
1/17 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
33.3%
1/3 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Respiratory, thoracic and mediastinal disorders
10037375-Pulmonary edema
|
5.9%
1/17 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Respiratory, thoracic and mediastinal disorders
10037400-Pulmonary hypertension
|
5.9%
1/17 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Respiratory, thoracic and mediastinal disorders
10040975-Sleep apnea
|
5.9%
1/17 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Respiratory, thoracic and mediastinal disorders
10041367-Sore throat
|
29.4%
5/17 • Number of events 6 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Respiratory, thoracic and mediastinal disorders
10047924-Wheezing
|
17.6%
3/17 • Number of events 3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Respiratory, thoracic and mediastinal disorders
Bilateral lower lobe interstitial changes possible infiltrates.
|
5.9%
1/17 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Respiratory, thoracic and mediastinal disorders
Emphysema
|
0.00%
0/17 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
33.3%
1/3 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Respiratory, thoracic and mediastinal disorders
LLL infiltrate
|
0.00%
0/17 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
33.3%
1/3 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Respiratory, thoracic and mediastinal disorders
Peribronchial infiltrate
|
5.9%
1/17 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Respiratory, thoracic and mediastinal disorders
Pneumonia
|
0.00%
0/17 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
33.3%
1/3 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Respiratory, thoracic and mediastinal disorders
Rales
|
0.00%
0/17 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
33.3%
1/3 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Respiratory, thoracic and mediastinal disorders
Right bundle branch block
|
5.9%
1/17 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Respiratory, thoracic and mediastinal disorders
chest infiltrate
|
0.00%
0/17 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
33.3%
1/3 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Respiratory, thoracic and mediastinal disorders
pneumonia
|
5.9%
1/17 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Respiratory, thoracic and mediastinal disorders
respiratory acidosis
|
5.9%
1/17 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Respiratory, thoracic and mediastinal disorders
tachypnea
|
5.9%
1/17 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Respiratory, thoracic and mediastinal disorders
vascular congestion
|
5.9%
1/17 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Skin and subcutaneous tissue disorders
10001760-Alopecia
|
0.00%
0/17 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
66.7%
2/3 • Number of events 2 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Skin and subcutaneous tissue disorders
10013786-Dry skin
|
17.6%
3/17 • Number of events 3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Skin and subcutaneous tissue disorders
10037087-Pruritus
|
35.3%
6/17 • Number of events 6 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Skin and subcutaneous tissue disorders
10037847-Rash acneiform
|
5.9%
1/17 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Skin and subcutaneous tissue disorders
10037868-Rash maculo-papular
|
64.7%
11/17 • Number of events 25 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
100.0%
3/3 • Number of events 3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Skin and subcutaneous tissue disorders
10040865-Skin hyperpigmentation
|
5.9%
1/17 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Skin and subcutaneous tissue disorders
10040947-Skin ulceration
|
11.8%
2/17 • Number of events 2 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Skin and subcutaneous tissue disorders
10051837-Skin induration
|
5.9%
1/17 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Skin and subcutaneous tissue disorders
10054524-Palmar-plantar erythrodysesthesia syndrome
|
5.9%
1/17 • Number of events 3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
33.3%
1/3 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Skin and subcutaneous tissue disorders
10054541-Periorbital edema
|
17.6%
3/17 • Number of events 4 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
33.3%
1/3 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Skin and subcutaneous tissue disorders
Ecchymosis
|
0.00%
0/17 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
33.3%
1/3 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Skin and subcutaneous tissue disorders
blisters
|
5.9%
1/17 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Skin and subcutaneous tissue disorders
desquamation in both hands
|
5.9%
1/17 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Skin and subcutaneous tissue disorders
nasal lesions
|
5.9%
1/17 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Skin and subcutaneous tissue disorders
petechial rash
|
11.8%
2/17 • Number of events 3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Vascular disorders
10007196-Capillary leak syndrome
|
5.9%
1/17 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Vascular disorders
10016825-Flushing
|
17.6%
3/17 • Number of events 3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Vascular disorders
10019428-Hematoma
|
5.9%
1/17 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Vascular disorders
10020772-Hypertension
|
94.1%
16/17 • Number of events 100 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
100.0%
3/3 • Number of events 4 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Vascular disorders
10021097-Hypotension
|
23.5%
4/17 • Number of events 10 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
|
Vascular disorders
10043565-Thromboembolic event
|
5.9%
1/17 • Number of events 1 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
0.00%
0/3 • Adverse event and vital status data were captured from the initial treatment to off study, up to 2 years.
From day 1 to day 30, the highest grade of non-hematologic toxicities were collected. For hematologic adverse events, from day 1 to day 30, collect every grade change for hematologic toxicities grade 3 and above. After the completion of treatment, report only the worst grade of each AE and only report AEs that are possibly, probably, or definitely related to Dasatinib.
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place